# Cipla’s US recovery, biosimilar pipeline key to future growth prospects — retained record

> Retained news record from news:india-et-markets.

Canonical: https://highsignal.app/data/records/a4f86052fb806db0

[← sources](https://highsignal.app/data)


source: [news](https://highsignal.app/data/news) (news:india-et-markets)  published 2026-10-28 00:19 ingested 2026-10-28 02:53

[original source ↗](https://economictimes.indiatimes.com/markets/stocks/earnings/cipla-q2-earnings-hit-by-us-market-challenges-india-growth-offers-support/articleshow/135248071.cms)

## retained text



```
Listen to this article in summarized format
India continues to remain the company's biggest growth engine, outperforming the overall domestic market. It delivered double-digit growth supported by respiratory, cardiac, anti-diabetes and dermatology therapies. With the rising share of chronic therapies and new product launches across segments, Cipla expects to sustain market share gains in the domestic business.
Read more: Vedanta Iron Q2 Results: Loss narrows to Rs 324 crore, revenue declines 2% YoY
While operating margin before depreciation and amortisation (Ebitda margin) declined 630 basis points year-on-year to 18.7%, it expanded 200 basis points sequentially amid tracion in the domestic business. It is expected to improve further in the second half of FY27, supported by respiratory product launches and a favourable product mix. It has retained the FY27 Ebitda margin guidance of 18.5%-20%.
Backed by a net cash position of ₹9,823 crore, Cipla is actively evaluating inorganic opportunities, particularly in North America and Europe, with a focus on acquiring complex and differentiated products that can strengthen its specialty portfolio.
Read more: Jio’s big-bang listing may give it stock market’s No.2 crown after Reliance Industries
Cipla's stock has lost over 4% over the past three months, underperforming the 2.5% drop in the BSE Healthcare index. Despite weakness, the stock's trailing price-earnings (P/E) multiple at around 38 is above its five-year average multiple of 27. The stock is likely to remain range-bound until a clear sign of recovery in revenue and profits emerges.
(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2025, Share Market on Budget 2025 and expert advice, on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .)
Subscribe to ET Prime and read the Economic Times ePaper Online.and Sensex Today.
Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price
(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2025, Share Market on Budget 2025 and expert advice, on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .)
Subscribe to ET Prime and read the Economic Times ePaper Online.and Sensex Today.
Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price
```



document fetched 2026-10-28 02:53